Erika Hamilton/LinkedIn
Aug 28, 2025, 15:15
Erika Hamilton Highlights MonarchE Trial Success in HR+ Breast Cancer
Erika Hamilton, Chair, Executive Committee Breast and Breast Program Lead at Sarah Cannon Research Institute, shared a post on LinkedIn:
“Fantastic news from monarchE – 2 years of adjuvant abemaciclib for patients with high risk HR+ Breast Cancer improves overall survival.
Happy for SCRI Oncology Partners, Sarah Cannon Research Institute to have participated in this trial and happy for our patients to have had access early. Translating more patients to cure is a very powerful way endpoint. ”
More posts featuring Erika Hamilton on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 28, 2025, 15:15
Aug 28, 2025, 14:58
Aug 28, 2025, 14:33
Aug 28, 2025, 14:22
Aug 28, 2025, 14:13
Aug 28, 2025, 14:03
Aug 28, 2025, 13:48